Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.

ABSTRACT:

Importance

There is currently no consensus as to which biomarkers best predict longitudinal tau accumulation at different clinical stages of Alzheimer disease (AD).

Objective

To describe longitudinal [18F]RO948 tau positron emission tomography (PET) findings across the clinical continuum of AD and determine which biomarker combinations showed the strongest associations with longitudinal tau PET and best optimized clinical trial enrichment.

Design, setting, and participants

This longitudinal cohort study consecutively enrolled amyloid-β (Aβ)-negative cognitively unimpaired (CU) participants, Aβ-positive CU individuals, Aβ-positive individuals with mild cognitive impairment (MCI), and individuals with AD dementia between September 2017 and November 2020 from the Swedish

SUBMITTER: Leuzy A 

PROVIDER: S-EPMC8689441 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature